Tacit Therapeutics Raises $19M in Series A Funding to Advance RNA Repair Therapies

Tacit Therapeutics just stepped out with the kind of funding that makes the biotech crowd lean a little closer to the stage. Not because it is loud. Because the science underneath it carries weight.

Tacit Therapeutics has secured $19M in Series A funding to advance its RNA repair platform, Splicing Directed Repair. The round was led by KdT Ventures with participation from Civilization Ventures, Eisai Innovation Inc., and Michigan Capital Network. Congratulations to CEO David Nelles and co founder Beatriz Osuna, VP of Research and Development, for getting this one across the line. In biotech, capital does not just show up because the pitch deck had pretty colors. It shows up when the science carries weight and the story makes investors lean forward.

Tacit Therapeutics is building around RNA trans splicing, a method designed to repair faulty RNA using the cell’s own machinery. No rewriting DNA. No permanent edits that might come back to haunt you later. Instead, the company is working to repair genetic messages at the RNA level before the cell turns those instructions into malfunctioning proteins. Quietly clever. Very Tacit, if you will. The approach is already showing promise in early work targeting Huntington’s disease, where repairing mutant RNA could shift the trajectory of devastating neurological decline.

The bigger picture here is what makes seasoned investors start circling the table. Gene editing has captured the spotlight for years, but RNA level repair introduces a different rhythm. Temporary, programmable, potentially safer. A way to fix the message without permanently altering the book it came from. When investors like KdT Ventures and Civilization Ventures step in alongside strategic players like Eisai Innovation Inc., it signals that people who understand the biology and the business see real platform potential.

For CEO David Nelles, this is a continuation of a career spent deep in the RNA trenches. Having previously co founded and served as CTO at Locanabio, David Nelles has been exploring the edges of RNA biology long before it became the industry’s latest fascination. Pair that experience with Beatriz Osuna’s platform leadership and research depth, and you get a founding duo that understands both the molecules and the mission. In biotech, credibility compounds just like capital.

The lesson here for founders is simple but rarely easy. Investors back platforms when the science is clear, the problem is massive, and the team has the scars and the curiosity to keep pushing through long development cycles. Tacit Therapeutics did not rush to the spotlight. They built the tech, sharpened the narrative, then stepped forward when the timing made sense.

Now the quiet company with the very on brand name has a louder runway. And if RNA repair delivers on even a slice of its promise, Tacit Therapeutics may end up proving that sometimes the most powerful moves in biotech start with a whisper.